Biocryst Pharmaceuticals buy Wedbush
Start price
30.06.25
/
50%
€7.60
Target price
30.06.26
€15.36
Performance (%)
-18.13%
Price
18.12.25
€6.22
Summary
This prediction is currently active. The prediction for Biocryst Pharmaceuticals disappoints with a performance of -18.13%. This prediction currently runs until 30.06.26. The prediction end date can be changed by Wedbush at any time. Wedbush has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Biocryst Pharmaceuticals | -7.413% | -7.413% |
| iShares Core DAX® | -1.212% | 1.925% |
| iShares Nasdaq 100 | -4.714% | -1.810% |
| iShares Nikkei 225® | -2.976% | -2.660% |
| iShares S&P 500 | -2.744% | -0.448% |
Comments by Wedbush for this prediction
In the thread Biocryst Pharmaceuticals diskutieren
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its price target raised by analysts at Wedbush from $16.00 to $18.00. They now have an "outperform" rating on the stock.
Ratings data for BCRX provided by MarketBeat
Stopped prediction by Wedbush for Biocryst Pharmaceuticals
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€7.80
25.02.25
25.02.25
€14.28
25.02.26
25.02.26
-20.25%
18.12.25
18.12.25
